CTOs on the Move

Ovid Therapeutics

www.ovidrx.com

 
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ovidrx.com
  • 1460 Broadway
    New York, NY USA 10036
  • Phone: 646.661.7661

Executives

Name Title Contact Details

Funding

Ovid Therapeutics raised $75M on 08/11/2015
Ovid Therapeutics raised $25.86M on 01/23/2017
Ovid Therapeutics raised $25M on 02/26/2019
Ovid Therapeutics raised $20M on 02/26/2019

Similar Companies

Presbyterian Senior Living

Supportive. Innovative. Compassionate. Presbyterian Senior Living is a not-for-profit organization, providing retirement and senior care services for more than 85 years. Headquartered in Dillsburg, Pennsylvania, we and our affiliates provide comprehensive services and accommodations to more than 6,000 seniors in 30 locations across the mid-Atlantic region of Pennsylvania, Maryland, Ohio and Delaware. Guided by the life and teachings of Jesus, the mission of Presbyterian Senior Living is to provide compassionate, vibrant and supportive communities and services to promote wholeness of body, mind and spirit.

Hilco/Wilson Smart Optical Solutions

Hilco/Wilson Smart Optical Solutions is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Plainville, MA. To find more information about Hilco/Wilson Smart Optical Solutions, please visit www.hilco-usa.com

Kinsa

We created the first FDA-cleared app-enabled thermometer because, from our work in the health systems within the U.S. and across impoverished nations throughout the world, we`ve learned that an elevated temperature is often the first sign of sickness. By building intelligence into a once basic thermometer and turning it into a connected device, we`re able to keep an eye on illnesses from beginning to end. We can more quickly alert users when fever and symptoms warrant closer monitoring or a visit to the doctor. Our network of connected thermometers can even offer helpful insights such as common illnesses that may be circulating in a local area or within a user`s school. Kinsa is ready to help whole communities better track, treat, and stop the spread of illness. But we know we`ll only do it if our products delight users from their first touch. It’s with this in mind that we developed the Kinsa Smart Thermometer.

Naveos

NAVEOS® is the proven leader in maximizing the value of governmental program reimbursements for healthcare providers. Since 2005, our superior approach to data analytics has enabled healthcare providers to realize almost one billion dollars in additional DSH/340B reimbursement payments. NAVEOS® has developed a fully integrated DSH/340B software solution with a national eligibility verification network for both Medicare and Medicaid data. This system, which is the most robust in the industry, uses sophisticated algorithms to match eligibility data with patient data, applies the most up to date Federal and State regulatory parameters, then builds comprehensive deliverables for supporting DSH/340B filings. By leveraging our state-of-the-art technology and unsurpassed domain expertise, we generate best-in-class deliverables that yield impressive value and achieve a stellar (99.7%) audit acceptance rate.

Boehringer Ingelheim

For more than 130 years, Boehringer Ingelheim has been committed to the research, development, and manufacturing of new medications with high therapeutic value for people and animals. As a family-owned pharmaceutical company, Boehringer Ingelheim is able to take a long-term view and invest heavily in research and development. We are proud of addressing some of the most challenging healthcare issues. Our vision – value through innovation – has always characterized our collaborative work, and is for us simultaneously a fundamental requirement and a driving force. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees.